Apoptosis Assay Market is Booming globally with Marginal Growth

Posted by Mrudula Karmarkar on January 17th, 2022

The global apoptosis assay market size is expected to reach USD 7.5 billion by 2027, expanding at a CAGR of 7.6%, according to a new report by Grand View Research, Inc. Extensive research activities on expanding applications of drug-induced apoptosis assays have propelled the inclination of pharmaceutical manufacturers towards incorporating cell cycle products in the drug discovery and designing process.

The introduction of affordable and easy to perform kits that can be accommodated in complex experiments is expected to minimize the overhead costs of apoptosis experiments. Companies are providing highly precise reagents and lot-to-lot reproducibility in sample measurements.

Professionals at pharmaceutical companies are making use of cell-cycle inhibitors and Apoptosis-Inducing Factors (AIF)/ molecules to explore possible drug targets. Also, high demand for caspase activity assays along with Bcl-2 protein family across pharmaceutical companies for apoptosis detection has been observed in recent years. Biotechnology companies are enhancing quantification techniques to enable real-time monitoring of apoptotic cellular dynamics.

The presence of established guidelines and protocols for cell-potency assays has strengthened the development of efficient cell-death detection assays. Whereas, stringent regulations with respect to the approval of cell-potency assays are ensuring successful uptake of market products launched. The flow cytometry segment dominated the market and accounted for the largest revenue share in 2020. This is attributed to the increasing adoption of the technique among researchers. It helps in finding the difference between intact mitochondria (healthy cells) and permeabilized mitochondria (cells undergoing death). The segment is anticipated to grow fast over the forecast period.

The pharmaceutical and biotechnology segment dominated the market in 2020 and is anticipated to continue its dominance over the forecast period. This is attributed to the rising incidence of cancer and neurodegenerative disorders. In addition, the growing significance of programmed cell death or apoptosis to treat chronic diseases is driving the segment growth.

To Request Sample Copy of this report, click the link:

https://www.grandviewresearch.com/industry-analysis/apoptosis-market/request/rs1

The cell death mechanism plays a key role in the onset and progression of several human chronic conditions, wherein cell-death assays have potential in designing strategies. These strategies are chiefly targeted toward modulating the apoptosis pathway for therapy development. In addition, wide acceptance of clinically useful cytoprotective and cytotoxic agents that can be used in the treatment of ischemic diseases, cancer, and neurodegenerative diseases has led to an increase in the adoption of High-Throughput Screening (HTS) assays; thereby driving the demand for cell-death assays over the years.

Apoptosis Assay Market Report Highlights

• The kits segment dominated the market and accounted for a revenue share of around 50.0% owing to increasing investment by key market players
• Increase in the demand for fluorochrome-labeled inhibitors of caspases has made reagents the fastest growing product segment in the market
• Application of these inhibitors with other techniques is anticipated to enhance the apoptosis assessment, thereby driving segment growth
• Owing to the wide adoption and easy availability of products, flow cytometry is estimated to account for a substantial share of approximately 35.0% in 2020
• The increasing significance of continuous monitoring of programmed cell death across novel drug discoveries and development of advanced therapeutics is set to propel market growth
• North America has dominated the market in terms of revenue share in 2020, and Asia Pacific is expected to witness the fastest growth in the coming years as a result of the expanding CRO landscape in the region
• Key companies are competing in terms of a combination of products and services in order to maintain market share.

Moreover, the advent of novel radionuclide tracers, such as caspase inhibitors and radiolabeled annexin V, has enhanced the efficiency of real-time monitoring of cellular death. For example, ANNEXIN V kits have undergone various modifications, with a growing preference toward radiolabeled ANNEXIN V kits. Controlling and understanding the mechanisms involved in different steps of apoptosis aid in novel drug discoveries. Also, high demand for caspase activity assays along with Bcl-2 protein family across pharmaceutical companies for cell death detection has propelled the market growth.

Key players in the market are contributing to market growth by providing services as well as a whole set of portfolios ranging from kits, reagents, and compatible instruments comprising readers and wash stations. In addition, companies are designing apoptosis assays specific to research needs which, in turn, are expected to increase the uptake of apoptosis assay products. Companies are providing consolidated solutions to researchers for better evaluation of the cell pathways. For instance, a combination of the flow cytometric assay with Annexin V and fluorescently conjugated antibodies is applicable for blood examination. Similarly, immunohistochemistry is combined with other markers for tissue examination. Some of the prominent players in the apoptosis assay market include:

• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories
• Bio-Techne
• Biotium
• GeneCopoeia, Inc.
• Becton, Dickinson & Company (BD)
• Thermo Fisher Scientific, Inc.
• Promega Corporation
• Sartorius AG
• Merck KGaA
• Abcam plc.
• Takara Bio Inc.